HB1501 (2022) Detail

Relative to insurance coverage for pediatric autoimmune neuropsychiatric disorders.


HB 1501-FN - AS INTRODUCED

 

 

2022 SESSION

22-2756

05/11

 

HOUSE BILL 1501-FN

 

AN ACT relative to insurance coverage for pediatric autoimmune neuropsychiatric disorders.

 

SPONSORS: Rep. McBeath, Rock. 26; Rep. Van Houten, Hills. 45; Rep. Abel, Graf. 13

 

COMMITTEE: Commerce and Consumer Affairs

 

-----------------------------------------------------------------

 

ANALYSIS

 

This bill repeals a prospective modification of RSA 417-E:1, III(f), regarding insurance coverage for pediatric autoimmune neuropsychiatric disorders.  In 2024, the phrase "when treatment, including the use of intravenous immunoglobulin therapy, is ordered by a physician" would have been removed from the statute.

 

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

 

Explanation: Matter added to current law appears in bold italics.

Matter removed from current law appears [in brackets and struckthrough.]

Matter which is either (a) all new or (b) repealed and reenacted appears in regular type.

22-2756

05/11

 

STATE OF NEW HAMPSHIRE

 

In the Year of Our Lord Two Thousand Twenty Two

 

AN ACT relative to insurance coverage for pediatric autoimmune neuropsychiatric disorders.

 

Be it Enacted by the Senate and House of Representatives in General Court convened:

 

1  Repeal; Pediatric Autoimmune Neuropsychiatric Disorders.  2019, 277:3, relative to a modification of insurance coverage for pediatric autoimmune neuropsychiatric disorders effective July 1, 2024, is repealed.

2  Effective Date.  This act shall take effect 60 days after its passage.

 

LBA

22-2756

11/23/21

 

HB 1501-FN- FISCAL NOTE

AS INTRODUCED

 

AN ACT relative to insurance coverage for pediatric autoimmune neuropsychiatric disorders.

 

FISCAL IMPACT:      [ X ] State              [ X ] County               [ X ] Local              [    ] None

 

 

 

Estimated Increase / (Decrease)

STATE:

FY 2022

FY 2023

FY 2024

FY 2025

   Appropriation

$0

$0

$0

$0

   Revenue

$0

$0

$0

Indeterminable

   Expenditures

$0

$0

$0

Indeterminable

Funding Source:

  [ X ] General            [    ] Education            [ X ] Highway           [ X ] Other - Various Government Funds

 

 

 

 

 

COUNTY:

 

 

 

 

   Revenue

$0

$0

$0

$0

   Expenditures

$0

$0

$0

Indeterminable

 

 

 

 

 

LOCAL:

 

 

 

 

   Revenue

$0

$0

$0

$0

   Expenditures

$0

$0

$0

Indeterminable

 

METHODOLOGY:

This bill repeals a prospective modification of RSA 417-E:1, III(f), regarding insurance coverage

for pediatric autoimmune neuropsychiatric disorders.  

 

The Insurance Department states this bill repeals the repeal of existing legislation that would be  effective on 7/1/2024 under current law.  The existing law mandates coverage for pediatric autoimmune neuropsychiatric disorders.  The law has been in effect for a short period and the Department has performed an analysis of claims.  However, the diagnosis code (D89.98) is not specific to just this patient population and cannot be relied upon to accurately identify claim costs therefore the impact of eliminating the repeal on claim costs and the insurance premium tax cannot be determined.  The Department noted the impact on claim costs would not necessarily inform the impact on premiums, or premium tax.  Issuers and purchasers may respond with premium increases, product design changes and buy-downs.  

 

AGENCIES CONTACTED:

Insurance Department

 

Links


Date Body Type
Feb. 2, 2022 House Hearing
Feb. 2, 2022 House Hearing
March 3, 2022 House Exec Session
Oct. 26, 2022 House Exec Session
House Floor Vote

Bill Text Revisions

HB1501 Revision: 34159 Date: Dec. 3, 2021, 2:54 p.m.

Docket


Oct. 27, 2022: Interim Study Report: Not Recommended for Future Legislation (Vote 17-0)


Oct. 10, 2022: Executive Session: 10/19/2022 10:00 am LOB 302-304


Sept. 28, 2022: Full Committee Work Session: 10/13/2022 11:00 am LOB 302-304


March 15, 2022: Refer for Interim Study: MA VV 03/15/2022 HJ 6


March 8, 2022: Committee Report: Refer for Interim Study (Vote 18-0; CC)


Feb. 28, 2022: Subcommittee Work Session: 03/03/2022 10:00 am LOB 302-304


March 3, 2022: Executive Session: 03/03/2022 1:15 p.m. LOB302-304


Feb. 3, 2022: Subcommittee Work Session: 02/10/2022 01:15 pm LOB 302-304


Feb. 2, 2022: Public Hearing: 02/02/2022 2:00 p.m. LOB302-304


Feb. 2, 2022: Public Hearing: 02/02/2022 2:00 p.m. LOB302-304


Dec. 3, 2021: Introduced 01/05/2022 and referred to Commerce and Consumer Affairs